This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Instinet Adds Favus Institutional Research As Exclusive IRP Partner

Instinet Incorporated, a global leader in electronic trading and agency-only brokerage services, today announced that its Instinet, LLC subsidiary has entered into an exclusive agreement with Favus Institutional Research, LLC, an independent research provider (IRP) that focuses on the healthcare sector. Under the terms of the agreement, Instinet will provide exclusive sales and marketing services for Favus.

Favus uses fundamental analysis to evaluate the sector, with a focus on commercial, clinical, legal, reimbursement and regulatory catalysts. Favus brings a successful forecast record, including the accuracy of its sell recommendations. As an independent research provider with no investment banking arm, Favus’s sole mission is to produce meaningful research for clients. Favus research is produced by Elliot Favus, M.D., a board-certified internist and former Och-Ziff and Lazard research analyst.

“We’re excited to expand our Access program with the addition of yet another high-quality IRP,” said Jonathan Kellner, President of the Americas at Instinet. “Favus delivers a unique offering in the healthcare research space that will enhance our ability to help our clients in the alpha generation process.”

“Instinet’s sophisticated trading platform and agency-only model make it a natural partner for us,” added Dr. Favus. “I am eager to combine our research product with Instinet's sales and trading capabilities.”

Favus Institutional Research becomes the seventh IRP in the Instinet Access program, which supports high-quality research providers with sales and marketing, account coverage, payment facilitation and other services across Instinet’s institutional client base and beyond.

About Favus Institutional Research, LLC

Favus Institutional Research is an independent healthcare equity research provider. The firm provides institutional investors with valuable healthcare research and divergent information, helping clients better assess healthcare stocks by analyzing information that is not ordinarily available from other research providers. Favus uses fundamental analysis to evaluate the healthcare sector, with a focus on commercial, clinical, legal, reimbursement and regulatory catalysts. The firm is headed by Elliot Favus, M.D., who has equity research and institutional investment management experience at Lazard Capital Markets and Och-Ziff Capital Management Group.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 18,265.65 -20.09 -0.11%
S&P 500 2,129.64 -1.18 -0.06%
NASDAQ 5,093.5560 +2.7620 0.05%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs